Interferon-alpha: mechanisms of action in chronic myelogenous leukemia in chronic phase.
Interferon-alpha has been shown to induce complete haematologic responses in chronic myelogenous leukemia patients and also cytogenetic responses. There is a clear correlation between cytogenetic responses and survival improvement. There is not a unique mechanism of action of IFN-alpha. IFN-alpha acts directly against leukemic cells and there are also other mechanisms of action such as immune stimulation, gene regulation and growth factors or interleukin stimulation.
Guilhot
F
F
Département d'Hématologie et Oncologie Médicale, Hôpital Jean Bernard, CHU la Milétrie, Poitiers, France.
Lacotte-Thierry
L
L
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D016760:Proto-Oncogene Proteins c-fos / Q000235:genetics; D014407:Tumor Cells, Cultured; D019014:fas Receptor / Q000235:genetics
D000970:Antineoplastic Agents; D016898:Interferon-alpha; D016760:Proto-Oncogene Proteins c-fos; D019014:fas Receptor